AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22691628 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib
Number of subjects: 35
Study 22691628 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib and Placebo
Number of subjects: 35
Study 19284395 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy and functional electrical stimulation
Number of subjects: 80
Study 19284395 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy only
Number of subjects: 80
Study 17545861 — intervention group
Group type: COMPARATOR
Intervention: Sublingual house dust-mite-specific immunotherapy for 2 years followed by 1 year of placebo (Group A)
Number of subjects: 137
Study 17545861 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual house dust-mite-specific immunotherapy for 3 years (Group B)
Number of subjects: 137
Study 14991953 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg + amoxicillin 1 000 mg + clarithromycin 250 mg)
Number of subjects: 132
Study 14991953 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC (omeprazole 20 mg + furazolidone 100 mg + clarithromycin 250 mg)
Number of subjects: 132
Study 14991953 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC (omeprazole 20 mg + metronidazole 200 mg + clarithromycin 250 mg)
Number of subjects: 132
Study 14991953 — intervention group
Group type: EXPERIMENTAL
Intervention: OFA (omeprazole 20 mg + furazolidone 100 mg + amoxicillin 1 000 mg)
Number of subjects: 132
Study 12217090 — intervention group
Group type: EXPERIMENTAL
Intervention: Six months of structured exercise program
Number of subjects: 174
Study 9642706 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-limb standing test for proprioception in ACL-deficient knee
Number of subjects: 32
Study 9642706 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 32
Study 8818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Memorizing positions of words
Number of subjects: 0
Study 8818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Memorizing words
Number of subjects: 0
Study 2689913 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine
Number of subjects: 40
Study 2689913 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 802922 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 0
Study 802922 — intervention group
Group type: EXPERIMENTAL
Intervention: Deglycyrrhizinized succus
Number of subjects: 0
Study 29799268 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic abrasion arthroplasty
Number of subjects: 26
Study 29799268 — intervention group
Group type: COMPARATOR
Intervention: Ligament reconstruction and tendon interposition (LRTI)
Number of subjects: 26
Study 28591155 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20
Study 28591155 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham)
Number of subjects: 20
Study 28591155 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg orally twice daily for five days)
Number of subjects: 20
Study 25957214 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis antibiotics
Number of subjects: 42
Study 25957214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24166282 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ixabepilone 16 mg/m2 as a 1-h IV infusion weekly on days 1, 8, and 15 of a 28-day cycle (1 week off therapy); n=85
Number of subjects: 176
Study 24166282 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-3-week ixabepilone 40 mg/m2 as a 3-h IV infusion on day 1 of a 21-day cycle; n=91
Number of subjects: 176
Study 21749265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilting Whole Body Vibration therapy (WBV) for 12 weeks (12.5-Hz frequency; 3-mm amplitude)
Number of subjects: 36
Study 21749265 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 19453534 — intervention group
Group type: COMPARATOR
Intervention: Standard Wedged Tangents (SWT)
Number of subjects: 20
Study 19453534 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangential Beam IMRT (T‐IMRT)
Number of subjects: 20
Study 19453534 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Coplanar Multi‐Field IMRT (NCP‐IMRT)
Number of subjects: 20
Study 19453534 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Compensators IMRT (E‐IMRT)
Number of subjects: 20
Study 19453534 — intervention group
Group type: EXPERIMENTAL
Intervention: Coplanar Multi‐Field IMRT (CP‐IMRT)
Number of subjects: 20
Study 17544776 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (1.25 mg)
Number of subjects: 165
Study 17544776 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 165
Study 17544776 — intervention group
Group type: COMPARATOR
Intervention: Combination of PDT with verteporfin and intravitreal bevacizumab
Number of subjects: 165
Study 15215482 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alpha-lactalbumin-oleic acid
Number of subjects: 40
Study 15215482 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study 15215482 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alpha-lactalbumin-oleic acid (second phase)
Number of subjects: 40
Study 15215482 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alpha-lactalbumin-oleic acid (long-term follow-up)
Number of subjects: 40
Study 11838750 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 175
Study 11838750 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 175
Study 9734615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal calcitriol
Number of subjects: 46
Study 9734615 — intervention group
Group type: COMPARATOR
Intervention: Oral calcitriol
Number of subjects: 46
Study 8090391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic saline amnioinfusion (600‐mL bolus followed by 3 mL/minute)
Number of subjects: 116
Study 8090391 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric care (control)
Number of subjects: 116
Study 3335145 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking six cigarettes
Number of subjects: 52
Study 3335145 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking
Number of subjects: 52
Study 31564843 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation) at Neiguan [PC6] and Ximen [PC4] for 30 minutes before anesthesia induction until the end of surgery
Number of subjects: 122
Study 31564843 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Number of subjects: 122
Study 31564843 — intervention group
Group type: COMPARATOR
Intervention: Control (electrode plate at the same acupuncture points without electrical stimulation)
Number of subjects: 122
Study 28487141 — intervention group
Group type: EXPERIMENTAL
Intervention: One large beverage (750kcal drink with 55 E% from carbohydrates)
Number of subjects: 14
Study 28487141 — intervention group
Group type: EXPERIMENTAL
Intervention: One large beverage (750kcal drink with 20 E% from carbohydrates)
Number of subjects: 14
Study 28487141 — intervention group
Group type: COMPARATOR
Intervention: Five 150kcal portions every 30min (low-carbohydrate meals)
Number of subjects: 14
Study 28487141 — intervention group
Group type: COMPARATOR
Intervention: Five 150kcal portions every 30min
Number of subjects: 14
Study 26112241 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) - 14 weeks, 3 sessions per week of four high-intensity cycling intervals
Number of subjects: 28
Study 26112241 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) - maintained normal level of physical activity
Number of subjects: 28
Study 23086904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearful face presentation during the Stroop task
Number of subjects: 36
Study 23086904 — intervention group
Group type: COMPARATOR
Intervention: Neutral face presentation during the Stroop task
Number of subjects: 36
Study 21474494 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual music therapy plus standard care (20 bi‐weekly sessions)
Number of subjects: 79
Study 21474494 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 79
Study 18284437 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐00734200 (0.3 to 300 mg)
Number of subjects: 27
Study 18284437 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐00734200 (10 mg)
Number of subjects: 27
Study 18284437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16460875 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Perception of Bladder Condition (PPBC)
Number of subjects: 1385
Study 16460875 — intervention group
Group type: EXPERIMENTAL
Intervention: Major PPBC improvement
Number of subjects: 1385
Study 12600849 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent consumption of fresh juices (especially berry juices)
Number of subjects: 324
Study 12600849 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for berry juice over other juices
Number of subjects: 324
Study 12600849 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of fermented milk products ≥ 3 times/week
Number of subjects: 324
Study 12600849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercourse frequency ≥ 3 times/week
Number of subjects: 324
Study 10839878 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA patch (5%‐1 g)
Number of subjects: 160
Study 10839878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 9244418 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV antigenemia assay
Number of subjects: 30
Study 9244418 — intervention group
Group type: COMPARATOR
Intervention: Viral culture
Number of subjects: 30
Study 9244418 — intervention group
Group type: COMPARATOR
Intervention: PCR
Number of subjects: 30
Study 9244418 — intervention group
Group type: COMPARATOR
Intervention: Shell vial
Number of subjects: 30
Study 9244418 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 30
Study 8401013 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mmol magnesium hydroxide daily for one year
Number of subjects: 468
Study 8401013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 3947901 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drains
Number of subjects: 100
Study 3947901 — intervention group
Group type: COMPARATOR
Intervention: No drainage (Control)
Number of subjects: 100
Study 29376112 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG+ (Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy)
Number of subjects: 53
Study 29376112 — intervention group
Group type: COMPARATOR
Intervention: NO-IVIG (No intravenous immunoglobulin with prednisone and risk-adapted chemotherapy)
Number of subjects: 53
Study 27250658 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sedation supplemented with pain management during mechanical ventilation
Number of subjects: 200
Study 27250658 — intervention group
Group type: COMPARATOR
Intervention: Sedation with a daily wake-up attempt
Number of subjects: 200
Study 24788209 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical polyvinyl alcohol (SPVA) microspheres
Number of subjects: 60
Study 24788209 — intervention group
Group type: COMPARATOR
Intervention: Tris-acryl gelatin (TAG) microspheres
Number of subjects: 60
Study 22206777 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg reslizumab
Number of subjects: 226
Study 22206777 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg reslizumab
Number of subjects: 226
Study 22206777 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg reslizumab
Number of subjects: 226
Study 22206777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 20452898 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 249
Study 17693107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 311
Study 17693107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 15948997 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg BIW
Number of subjects: 583
Study 15948997 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg BIW
Number of subjects: 583
Study 15948997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study 15948997 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg BIW (after dose reduction from 50 mg)
Number of subjects: 583
Study 15948997 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg BIW (continuous)
Number of subjects: 583
Study 15948997 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by etanercept 25 mg BIW
Number of subjects: 583
Study 15189622 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motive scores when motivational content was present in emotional memory
Number of subjects: 0
Study 15189622 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit motive scores when motivational content was present in self-descriptive memory
Number of subjects: 0
Study 15189622 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motive scores for recalling specific agentic and communal events
Number of subjects: 0
Study 15189622 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit motive scores for recalling general achievement events
Number of subjects: 0
Study 15189622 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit motive scores for recalling general communal events
Number of subjects: 0
Study 10225167 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 8.0% end-tidal concentration
Number of subjects: 64
Study 10225167 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 7.9% end-tidal concentration
Number of subjects: 64
Study 8902255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate (1,200 mg daily for 12 weeks)
Number of subjects: 214
Study 8902255 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg daily for 12 weeks)
Number of subjects: 214
Study 8902255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 8902255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate
Number of subjects: 214
Study 8902255 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 214
Study 1854763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 15
Study 1854763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 6141089 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin induced labor
Number of subjects: 166
Study 6141089 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous labor
Number of subjects: 166
Study 31440862 — intervention group
Group type: EXPERIMENTAL
Intervention: 1FOOT (one 60-min football session)
Number of subjects: 15
Study 31440862 — intervention group
Group type: EXPERIMENTAL
Intervention: 3FOOT (three 60-min football sessions)
Number of subjects: 15
Study 26267390 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check Up (FCU) intervention
Number of subjects: 0
Study 26267390 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27460541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day for 12 weeks
Number of subjects: 25
Study 24607594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle training (four sessions of 45 min)
Number of subjects: 94
Study 24607594 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study 22486894 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline followed by 2% chlorhexidine gluconate (CHX)
Number of subjects: 55
Study 22486894 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% citric acid (CA) followed by 2% CHX
Number of subjects: 55
Study 22486894 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% EDTA followed by 2% CHX
Number of subjects: 55
Study 22486894 — intervention group
Group type: COMPARATOR
Intervention: Negative control (not specified)
Number of subjects: 55
Study 20370923 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of surgery and trocar techniques (Group B)
Number of subjects: 180
Study 20370923 — intervention group
Group type: COMPARATOR
Intervention: Classical surgical technique (Group A)
Number of subjects: 180
Study 20370923 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TM (Group A)
Number of subjects: 180
Study 20370923 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without TM (Group A)
Number of subjects: 180
Study 17711710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban bolus (10 microg/kg) prior to the first balloon inflation (Group IC)
Number of subjects: 60
Study 17711710 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tirofiban bolus (10 microg/kg) prior to coronary angiography (Group IV)
Number of subjects: 60
Study 17711710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban (Group IC)
Number of subjects: 60
Study 17711710 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tirofiban (Group IV)
Number of subjects: 60
Study 15386771 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of surveillance and/or preventative strategies for reduction of ovarian cancer risk
Number of subjects: 129
Study 15386771 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for screening as a risk management option
Number of subjects: 129
Study 15386771 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for information about ovarian cancer
Number of subjects: 129
Study 15386771 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for shared decision-making
Number of subjects: 129
Study 12093600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone (0.3 mg/kg)
Number of subjects: 39
Study 12093600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10367037 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA scanner calibration shift during clinical trial
Number of subjects: 0
Study 10367037 — intervention group
Group type: COMPARATOR
Intervention: Standard quality control procedures using phantoms
Number of subjects: 0
Study 7551371 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (5-lipoxygenase inhibitor)
Number of subjects: 10
Study 2165088 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (75 micrograms twice daily)
Number of subjects: 559
Study 2165088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559
Study 2165088 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine plus chlorthalidone (15 mg)
Number of subjects: 559
Study 2165088 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chlorthalidone (15 mg)
Number of subjects: 559
Study 91439 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug combination chemotherapy program containing cis-dichlorodiammineplatinum(II)
Number of subjects: 25
Study 31421669 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, tablet-based physiotherapy training programme
Number of subjects: 0
Study 29284686 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 21
Study 29284686 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 21
Study 29284686 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg)
Number of subjects: 21
Study 29284686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 26482910 — intervention group
Group type: EXPERIMENTAL
Intervention: OSU6162
Number of subjects: 56
Study 26482910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 23104129 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 239
Study 23104129 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 239
Study 21843222 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time automated feedback during chest compressions
Number of subjects: 0
Study 21843222 — intervention group
Group type: COMPARATOR
Intervention: No feedback during chest compressions
Number of subjects: 0
Study 19434566 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPPS
Number of subjects: 79
Study 19434566 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 79
Study 19434566 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 79
Study 16751033 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of daily patching with 1 hour of near visual activities
Number of subjects: 180
Study 16751033 — intervention group
Group type: COMPARATOR
Intervention: Spectacles alone (if needed)
Number of subjects: 180
Study 15289492 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SPES (3 capsules orally three times a day)
Number of subjects: 90
Study 15289492 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES, 3 mg orally once a day)
Number of subjects: 90
Study 12451007 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of mineral water
Number of subjects: 13
Study 9720812 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy against birch pollen
Number of subjects: 24
Study 9720812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 24
Study 7705114 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable barrier filter (Pall Biomedical, United Kingdom)
Number of subjects: 25
Study 2784949 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 2784949 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 40
Study 566734 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise
Number of subjects: 55
Study 566734 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal exercise regimens
Number of subjects: 55
Study 566734 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (general)
Number of subjects: 55
Study 566734 — intervention group
Group type: COMPARATOR
Intervention: Control programme
Number of subjects: 55
Study 31872340 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise first (Group C)
Number of subjects: 88